×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [21]
合肥物质科学研究院 [10]
北京大学 [2]
武汉病毒研究所 [2]
上海生物化学与细胞生... [2]
江苏大学 [1]
更多...
内容类型
期刊论文 [41]
发表日期
2023 [1]
2022 [3]
2021 [3]
2020 [6]
2019 [4]
2018 [8]
更多...
学科主题
Oncology [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共41条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
期刊论文
ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13
作者:
Hua, Chen
;
Shena, Lijuan
;
Zoua, Fengming
;
Wua, Yun
;
Wanga, Beilei
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2023/11/10
Acquired resistance mutations
CDK9 inhibitors
Transcription
Single nucleotide polymorphisms
BAY1251152
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
期刊论文
MOLECULAR CANCER, 2022, 卷号: 21
作者:
Zhu, Chunxiao
;
Guan, Xiaoqing
;
Zhang, Xinuo
;
Luan, Xin
;
Song, Zhengbo
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
KRAS mutations
Druggable
Resistance
Combination therapy
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
期刊论文
NPJ PRECISION ONCOLOGY, 2022, 卷号: 6
作者:
Zhang, Yongchang
;
Huang, Zhe
;
Zeng, Liang
;
Zhang, Xiangyu
;
Li, Yizhi
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2022/05/05
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers
期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:
Cao, Jiang-yan
;
Qi, Shuang
;
Wu, Hong
;
Wang, Ao-li
;
Liu, Qing-wang
收藏
  |  
浏览/下载:89/0
  |  
提交时间:2022/03/28
HER2
breast cancers
gastric cancers
irreversible inhibitor
drug resistance
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:
Liu, Yingqiang
;
Lai, Mengzhen
;
Li, Shan
;
Wang, Yanan
;
Feng, Fang
收藏
  |  
浏览/下载:58/0
  |  
提交时间:2022/01/18
C797S
epidermal growth factor receptor
fourth-generation EGFR TKI
non-small cell lung cancer
osimertinib resistance
Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance
期刊论文
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 卷号: 202
作者:
Li, Na
;
Mao, Weimin
;
Gao, Yun
;
Wang, Ding
;
Song, Zhengbo
收藏
  |  
浏览/下载:47/0
  |  
提交时间:2021/08/31
Lung cancer
EGFR-TKI
Resistance
Pleural effusion
Metabolomics
Biomarker
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
期刊论文
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:
Lu, Tingting
;
Cao, Jiangyan
;
Zou, Fengming
;
Li, Xixiang
;
Wang, Aoli
收藏
  |  
浏览/下载:39/0
  |  
提交时间:2021/04/26
BCR-ABL
ABL mutants
Chronic myeloid leukemia
Kinase inhibitor
Imatinib resistance
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 7
作者:
Xia, Zong-jun
;
Ji, Yin-chun
;
Sun, De-qiao
;
Peng, Xia
;
Gao, Ying-lei
收藏
  |  
浏览/下载:75/0
  |  
提交时间:2020/12/21
ROS1 kinase
ROS1 inhibitor
SAF-189s
lorlatinib
crizotinib resistance
G2032R mutant
NSCLC
Progress on treatment of MET signaling pathway in non-small cell lung cancer
期刊论文
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020
作者:
Yu, Xiaoqing
;
Yu, Sizhe
;
Fan, Yun
收藏
  |  
浏览/下载:24/0
  |  
提交时间:2020/11/26
MET
Dysregulation
Overexpression
Amplification
Non-small cell lung cancer
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
期刊论文
MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15
作者:
Zhang, Tao
;
Qu, Rong
;
Chan, Shingpan
;
Lai, Mengzhen
;
Tong, Linjiang
收藏
  |  
浏览/下载:39/0
  |  
提交时间:2020/07/01
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
©版权所有 ©2017 CSpace - Powered by
CSpace